Different effects of linagliptin and sitagliptin on blood pressure and renal function in Japanese patients with type 2 diabetes mellitus

• Published in: Diabetology international Vol. 8; no. 4; pp. 397 - 401
• Main Authors: Tojikubo, Masayuki, Tajiri, Yuji
• Format: Journal Article
• Language: English
• Published: Tokyo Springer Japan 01-11-2017; Springer Nature B.V
• Subjects: Blood pressure; Creatinine; Diabetes; Diabetes mellitus; Endocrinology; Epidermal growth factor receptors; Excretion; Hemodynamics; Medicine; Medicine & Public Health; Metabolic Diseases; Renal function; Short Communication; Uric acid; eGFR; Type 2 diabetes; Sitagliptin; Linagliptin; Blood pressure
• ISSN: 2190-1678; 2190-1686
• DOI: 10.1007/s13340-017-0320-4

Aims
To compare and evaluate effects of two DPP-4 inhibitors with different excretion routes on systemic and renal hemodynamics in Japanese patients with type 2 diabetes mellitus.
Methods
Seventy-three outpatients with type 2 diabetes who had been treated by 50 mg/day of sitagliptin (S) for at least 1 year were enrolled and prescribed 5 mg/day of linagliptin (L) instead of S for the next 1 year.
Results
After the initiation of S, the systolic and diastolic blood pressure decreased significantly. However, after switching to L for 1 year they increased significantly and returned to a comparable level as those before S treatment. The increase in serum creatinine or uric acid levels and the decrease in eGFR after S initiation were completely stopped or reversed after switching to L. The change in eGFR after the initiation of S was negatively correlated with the eGFR value at 1 year before switching.
Conclusions
The administration of S had an obvious effect on the systemic or renal hemodynamics in contrast to the fact that the administration of L had no effect on these parameters. It is thus important to use these agents with different excretion routes, properly taking the patients' renal function into account.